Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
about
Impact of epithelial ovarian cancer screening on patient-relevant outcomes in average-risk postmenopausal womenOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionIn 2014, can we do better than CA125 in the early detection of ovarian cancer?Discovery of new biomarkers for malignant mesotheliomaCancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screeningOvarian cancer screening--current status, future directionsCancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screeningProteomics of ovarian cancer: functional insights and clinical applicationsPilot Clinical Evaluation of a Confocal Microlaparoscope for Ovarian Cancer Detection.The effect of time on racial differences in epithelial ovarian cancer (OVCA) diagnosis stage, overall and by histologic subtypes: a study of the National Cancer Database.iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancerIncessant ovulation and ovarian cancer - a hypothesis re-visitedThe impact of continuous Medicaid enrollment on diagnosis, treatment, and survival in six surgical cancers.Confocal microlaparoscope for imaging the fallopian tubeModeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early DetectionLosing touch? Refining the role of physical examination in family medicine.Recommendations for lab-based screening tests for adult women.Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyondTime to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancerMathematical models of breast and ovarian cancers.Diagnostic potential of tumor DNA from ovarian cyst fluid.Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-UpThe prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes.Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.Accuracy of ovarian and colon cancer risk assessments by U.S. physicians.Psychological and Behavioral Impact of Participation in Ovarian Cancer Screening.A review of iniparib in ovarian cancer.Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.Hereditary ovarian and breast cancer: what have we learned?Should the annual pelvic examination go the way of annual cervical cytology?Ovarian cancer: diagnostic, biological and prognostic aspects.The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.microRNA and Ovarian Cancer.Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result.Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.Estimating the Prevalence of Ovarian Cancer Symptoms in Women Aged 50 Years or Older: Problems and PossibilitiesPatterns of cancer screening in primary care from 2005 to 2010.
P2860
Q24195062-1C5C5C5D-14C6-4DA3-AC07-40A5D0B5CF66Q26747279-D6EB22CE-0C66-4088-878D-1A660828B9AAQ26825152-002B0251-84B8-45A7-876F-4F83A3D538C5Q26849620-2B5C2635-9828-4D3A-8013-FE016CE9FFEAQ27001043-11C27E5C-ABC3-459C-A369-1CD1F06B4243Q27004471-C12F788C-0DD2-45B3-BB90-DC2E81F4A6B9Q27025805-9C77FDC2-FF6C-4A9E-89BF-72D0AFE67EADQ28082632-A58ED469-5F52-4F54-BD9C-8912BE1A509FQ30701684-4BD24AC7-0DA8-4C8D-A6FC-1AF32739D282Q33639932-3C4C0CEB-2C05-4ACE-A109-7F3031707F43Q33779349-5185AA01-9D23-41DA-A7DA-A543D78E0833Q34416449-CC04AEED-CF8B-4CE0-B24E-2E8FC7D632DBQ34623027-01FF1D50-F386-4082-A463-92F71B75B0B7Q35535613-2D2FFA45-3340-4916-B77B-164A6E9D1653Q36039369-1732FBB2-412F-403A-80FE-240EE399474BQ36368643-70BEA878-8C7B-4A65-8268-3A3A2EF57E88Q36528196-EFFC73D5-6ECE-4F98-B52A-DC476E055481Q36619933-F5FB58E8-7DC1-4B39-8F5C-5BAF25DBDA65Q36866311-E7E4CCE4-D819-494E-BCAB-93DB4BF4368DQ36894026-CD54749F-C71A-441E-8313-545A1798F765Q37014152-92DC4F50-8406-4C67-ADA7-24380058BD78Q37098838-225EE3BA-D514-4474-B9B9-81E479152F42Q37234775-DD4411D5-1712-483E-BB81-68722DBB1463Q37463616-365A6D33-0C80-4150-A18D-D325EB25E47FQ37594361-0DA2A7F6-E887-47A5-8DB3-FAF2F24CE1CEQ37620476-E65F5AEB-0A68-4228-A358-4A4DF79FC3E0Q37724409-41D413BD-4E3F-4D98-85E0-162BE5656750Q37729983-763766CD-40B9-4FC8-AA98-4D3336B0FCE0Q38080153-56E6CAED-369A-40EF-8423-6334B7C740D1Q38093037-7028A3E5-7722-47A7-B926-23794AA2EB95Q38153188-25198557-A3AA-4BED-B410-1540376535CFQ38254648-3EB92743-437D-48DC-82CE-3F5A36AAEBFBQ38261795-2D219B4C-5107-4868-B838-6EBF2D263D5CQ38653169-E93B74F4-455F-431D-A6D9-0EE8BDDDBB0AQ38667018-42A7717D-E037-4D76-861A-DF57D0662E2AQ38692120-6B296409-5D20-40AE-A8C9-212261627992Q38711217-A53C6198-655C-4467-9C12-C786AC932A5CQ38750652-10A991EF-8536-49C6-8096-BBEF731817B1Q39294212-58819C04-16E6-4284-A7BB-E5727206DC34Q40146311-7A193167-B945-462A-97DB-C9EFC83FA9D7
P2860
Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Screening for ovarian cancer: ...... tion recommendation statement.
@ast
Screening for ovarian cancer: ...... tion recommendation statement.
@en
Screening for ovarian cancer: ...... tion recommendation statement.
@nl
type
label
Screening for ovarian cancer: ...... tion recommendation statement.
@ast
Screening for ovarian cancer: ...... tion recommendation statement.
@en
Screening for ovarian cancer: ...... tion recommendation statement.
@nl
prefLabel
Screening for ovarian cancer: ...... tion recommendation statement.
@ast
Screening for ovarian cancer: ...... tion recommendation statement.
@en
Screening for ovarian cancer: ...... tion recommendation statement.
@nl
P1476
Screening for ovarian cancer: ...... tion recommendation statement.
@en
P2093
U.S. Preventive Services Task Force
Virginia A Moyer
P304
P356
10.7326/0003-4819-157-11-201212040-00539
P407
P577
2012-12-01T00:00:00Z